Copyright
©The Author(s) 2017.
World J Gastroenterol. Jun 14, 2017; 23(22): 4072-4079
Published online Jun 14, 2017. doi: 10.3748/wjg.v23.i22.4072
Published online Jun 14, 2017. doi: 10.3748/wjg.v23.i22.4072
Table 2 Change of clinical indices before and after combined directly acting antivirals treatment
T0 | T1 | T2 | P01 | P12 | P02 | P(DAAs*Time) | |
FIB-4 score | 4.07 ± 4.35 | 2.94 ± 2.76 | 2.61 ± 2.21 | 0.001 | 0.003 | < 0.001 | 0.399 |
ALT (IU/L) | 54.6 ± 36.3 | 20.3 ± 13.3 | 17.1 ± 6.9 | < 0.001 | 0.061 | < 0.001 | 0.594 |
AST (IU/L) | 50.8 ± 33.1 | 24.4 ± 10.4 | 22.4 ± 7.0 | < 0.001 | 0.006 | < 0.001 | 0.733 |
eGFR(mL/min/1.73 m2) | 87.1 ± 19.5 | 81.2 ± 20.0 | 83.6 ± 21.2 | 0.001 | 0.174 | 0.097 | 0.646 |
Scr (μmol/L) | 83.6 ± 17.9 | 88.8 ± 19.4 | 86.8 ± 19.1 | < 0.001 | 0.137 | 0.039 | 0.481 |
UA (μmol/L) | 320.8 ± 76.3 | 354.5 ± 87.6 | 345.9 ± 89.4 | < 0.001 | 0.212 | 0.001 | 0.299 |
BUN (mmol/L) | 5.17 ± 1.50 | 5.12 ± 1.40 | 5.65 ± 1.80 | 0.757 | 0.003 | 0.009 | 0.858 |
WBC (109/L) | 4.85 ± 1.67 | 4.91 ± 1.54 | 5.00 ± 1.34 | 0.725 | 0.595 | 0.342 | 0.536 |
RBC (1012/L) | 4.42 ± 0.64 | 4.43 ± 0.68 | 4.50 ± 0.68 | 0.822 | 0.345 | 0.223 | 0.023 |
HGB (g/L) | 140.8 ± 17.2 | 139.4 ± 20.9 | 141.1 ± 21.1 | 0.467 | 0.443 | 0.860 | 0.026 |
PLT (109/L) | 147.1 ± 65.1 | 153.6 ± 67.5 | 158.2 ± 65.9 | 0.053 | 0.117 | 0.008 | 0.540 |
- Citation: Chen JH, Zeng Z, Zhang XX, Zhang Y, Zhang RW, Wang S, Wu CH, Yu M, Liu D, Xi HL, Zhou YX, An YY, Xu XY. Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting. World J Gastroenterol 2017; 23(22): 4072-4079
- URL: https://www.wjgnet.com/1007-9327/full/v23/i22/4072.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i22.4072